Paolo Durigutto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9030308/publications.pdf

Version: 2024-02-01

25 papers	1,767 citations	331538 21 h-index	580701 25 g-index
28 all docs	28 docs citations	28 times ranked	2454 citing authors

#	Article	IF	Citations
1	Thrombus formation induced by antibodies to Î²2-glycoprotein I is complement dependent and requires a priming factor. Blood, 2005, 106, 2340-2346.	0.6	324
2	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nature Communications, 2016, 7, 10346.	5.8	224
3	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110, 536-543.	0.6	121
4	A nonâ€“complement-fixing antibody to Î²2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 2014, 123, 3478-3487.	0.6	120
5	In vivo distribution of Î²2 glycoprotein I under various pathophysiologic conditions. Blood, 2011, 118, 4231-4238.	0.6	113
6	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nature Reviews Rheumatology, 2018, 14, 433-440.	3.5	95
7	Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2009, 124, 1303-1310.e4.	1.5	94
8	The Neutrophil-Activating Protein of Helicobacter pylori Crosses Endothelia to Promote Neutrophil Adhesion In Vivo. Journal of Immunology, 2007, 178, 1312-1320.	0.4	87
9	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood, 2016, 127, 365-367.	0.6	67
10	Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia, 2015, 29, 406-414.	3.3	64
11	Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clinical and Experimental Immunology, 2004, 135, 186-193.	1.1	62
12	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines, 2021, 9, 1003.	1.4	44
13	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica, 2019, 104, 819-826.	1.7	40
14	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis and Rheumatism, 2012, 64, 2559-2567.	6.7	39
15	Mannose-binding lectin is produced by vaginal epithelial cells and its level in the vaginal fluid is influenced by progesterone. Molecular Immunology, 2010, 48, 281-286.	1.0	38
16	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. Journal of Autoimmunity, 2019, 103, 102288.	3.0	33
17	Orchestration of Inflammation and Adaptive Immunity in Borrelia burgdorferiâ€“Induced Arthritis by Neutrophilâ€Activating Protein A. Arthritis and Rheumatism, 2013, 65, 1232-1242.	6.7	32
18	Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. Journal of Immunology, 2015, 195, 5602-5607.	0.4	30

#	Article	IF	Citations
19	Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis and Rheumatism, 2007, 56, 1187-1197.	6.7	29
20	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. Transplantation, 2008, 86, 1445-1451.	0.5	24
21	Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. PLoS ONE, 2013, 8, e58696.	1.1	24
22	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Frontiers in Immunology, 2017, 8, 1093.	2.2	20
23	Complement Activation and Thrombin Generation by MBL Bound to Î²2-Glycoprotein I. Journal of Immunology, 2020, 205, 1385-1392.	0.4	16
24	Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes. Atherosclerosis, 2011, 216, 83-89.	0.4	11
25	Control of arthritis by local synthesis of recombinant antibody neutralizing C5. Immunobiology, 2012, 217, 1160-1161.	0.8	0